BLAINJECTIONINJECTABLE
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ACCRETROPIN (somatropin) by Emergent BioSolutions is cells. Approved for growth hormone deficiency, turner syndrome, small for gestational age and 1 more indications. First approved in 2008.
Drug data last refreshed 20h ago
Mechanism of Action
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1,…
Indications (4)
Worked on ACCRETROPIN at Emergent BioSolutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.